Lien Lybaert
Research Subjects
Lien Lybaert has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Bruno G. De Geest
Department of Pharmaceutics Ghent University Ghent Belgium
3 shared publications - Aaron P. Esser-Kahn
University of Chicago
2 shared publications Alfred C. Chon
Department of Chemistry, University of California, Irvine, California, 92697 United States
2 shared publicationsKeun Ah Ryu
Department of Chemistry, University of California, Irvine, California, 92697 United States
2 shared publications- Lutz Nuhn
Institute of Functional Materials and Biofabrication Center of Polymers for Life Universität Würzburg Würzburg Germany
2 shared publications Olivier De Wever
Laboratory of Experimental Cancer Research, Ghent University, 9000 Ghent, Belgium
2 shared publications
Latest Publications
- Open Access
Accelerating Neoantigen Discovery: A High-Throughput Approach to Immunogenic Target Identification
Background: Antigen-targeting immunotherapies hinge on the accurate identification of immunogenic epitopes that elicit robust T-cell responses. However, current computational approaches focus primarily on MHC binding affinity, leading to high false-positive rates and limiting the clinical utility of antigen selection methods. Methods: We developed the neoIM (for “neoantigen immunogenicity”) model, a first-in-class, high-precision immunogenicity prediction tool that overcomes these limitations by focusing exclusively on overall CD8 T-cell response rather than MHC binding. neoIM, a random forest classifier, was trained solely on MHC-presented non-self peptides (n = 61.829). Its performance was assessed against that of currently existing alternatives on several in vitro immunogenicity datasets. In addition, its clinical impact was investigated in two retrospective analyses of clinical trial data by assessing the effect of neoIM-based antigen selection on the positive immunogenicity rate of personal vaccine designs. Finally, the potential for neoIM as a biomarker was investigated by assessing the correlation between neoIM scores and overall survival in a melanoma patient cohort treated with checkpoint inhibitors (CPI). Results: neoIM was found to substantially outperform publicly available tools in regards to in vitro benchmarks based on ELISpot assays, with an increase in predictive power of at least 30%, reducing false positives and improving target selection efficiency. In addition, using neoIM scores during patient-specific antigen prioritization and selection was shown to yield up to 50% more clinically actionable antigens for individual patients in two recent clinical trials. Finally, we showed that neoIM could further refine response prediction to checkpoint inhibition therapy, further demonstrating the importance of evaluating neoantigen immunogenicity. Conclusions: These findings establish neoIM as the first computational tool capable of accurately predicting epitope immunogenicity beyond MHC affinity. By enabling more precise target discovery and prioritization, neoIM has the potential to accelerate the development of next-generation antigen-based immunotherapies.
Open AccessAccelerating Neoantigen Discovery: A High-Throughput Approach to Immunogenic Target Identification
Background: Antigen-targeting immunotherapies hinge on the accurate identification of immunogenic epitopes that elicit robust T-cell responses. However, current computational approaches focus primarily on MHC binding affinity, leading to high false-positive rates and limiting the clinical utility of antigen selection methods. Methods: We developed the neoIM (for “neoantigen immunogenicity”) model, a first-in-class, high-precision immunogenicity prediction tool that overcomes these limitations by focusing exclusively on overall CD8 T-cell response rather than MHC binding. neoIM, a random forest classifier, was trained solely on MHC-presented non-self peptides (n = 61.829). Its performance was assessed against that of currently existing alternatives on several in vitro immunogenicity datasets. In addition, its clinical impact was investigated in two retrospective analyses of clinical trial data by assessing the effect of neoIM-based antigen selection on the positive immunogenicity rate of personal vaccine designs. Finally, the potential for neoIM as a biomarker was investigated by assessing the correlation between neoIM scores and overall survival in a melanoma patient cohort treated with checkpoint inhibitors (CPI). Results: neoIM was found to substantially outperform publicly available tools in regards to in vitro benchmarks based on ELISpot assays, with an increase in predictive power of at least 30%, reducing false positives and improving target selection efficiency. In addition, using neoIM scores during patient-specific antigen prioritization and selection was shown to yield up to 50% more clinically actionable antigens for individual patients in two recent clinical trials. Finally, we showed that neoIM could further refine response prediction to checkpoint inhibition therapy, further demonstrating the importance of evaluating neoantigen immunogenicity. Conclusions: These findings establish neoIM as the first computational tool capable of accurately predicting epitope immunogenicity beyond MHC affinity. By enabling more precise target discovery and prioritization, neoIM has the potential to accelerate the development of next-generation antigen-based immunotherapies.
- 1 November 2018
- Published by Elsevier in Journal of Controlled Release
- Vol. 289, 125-145
Immunoengineering through cancer vaccines – A personalized and multi-step vaccine approach towards precise cancer immunity
- 1 November 2018
- Published by Elsevier in Journal of Controlled Release
- Vol. 289, 125-145
Immunoengineering through cancer vaccines – A personalized and multi-step vaccine approach towards precise cancer immunity
- Open Access
- 2 May 2017
- Published by Wiley in Advanced Science
- Vol. 4 (6) , 1700050
Polyelectrolyte‐Enrobed Cancer Cells in View of Personalized Immune‐Therapy
Targeting the immune system with a personalized vaccine containing cues derived from the patient's malignancy might be a promising approach in the fight against cancer. It includes neo‐antigens as well as nonmutated tumor antigens, preferentially leading to an immune response that is directed to a broader range of epitopes compared to strategies involving a single antigen. Here, this paper reports on an elegant method to encapsulate whole cancer cells into polyelectrolyte particles. Porous and nonaggregated microparticles containing dead cancer cells are obtained by admixing mannitol and live cancer cells with oppositely charged polyelectrolytes, dextran sulfate (anionic polysaccharide), and poly‐l‐arginine (cationic polypeptide) prior to atomization into a hot air stream. It shows that the polyelectrolyte‐enrobed cancer cells, upon redispersion in phosphate buffered saline buffer, are stable and do not release cell proteins in the supernatant. In vitro experiments reveal that the particles are nontoxic and strongly increase uptake of cell lysate by dendritic cells. In vitro assessment of antigen presentation by dendritic cells reveal the potential of the polyelectrolyte‐enrobed cancer cells as promotors of antigen cross‐presentation. Finally, it is demonstrated that the immunogenicity can be enhanced by surface adsorption of a polymer‐substituted TLR7‐agonist.
- 2 May 2017
- Published by Wiley in Advanced Science
- Vol. 4 (6) , 1700050
Open AccessPolyelectrolyte‐Enrobed Cancer Cells in View of Personalized Immune‐Therapy
Targeting the immune system with a personalized vaccine containing cues derived from the patient's malignancy might be a promising approach in the fight against cancer. It includes neo‐antigens as well as nonmutated tumor antigens, preferentially leading to an immune response that is directed to a broader range of epitopes compared to strategies involving a single antigen. Here, this paper reports on an elegant method to encapsulate whole cancer cells into polyelectrolyte particles. Porous and nonaggregated microparticles containing dead cancer cells are obtained by admixing mannitol and live cancer cells with oppositely charged polyelectrolytes, dextran sulfate (anionic polysaccharide), and poly‐l‐arginine (cationic polypeptide) prior to atomization into a hot air stream. It shows that the polyelectrolyte‐enrobed cancer cells, upon redispersion in phosphate buffered saline buffer, are stable and do not release cell proteins in the supernatant. In vitro experiments reveal that the particles are nontoxic and strongly increase uptake of cell lysate by dendritic cells. In vitro assessment of antigen presentation by dendritic cells reveal the potential of the polyelectrolyte‐enrobed cancer cells as promotors of antigen cross‐presentation. Finally, it is demonstrated that the immunogenicity can be enhanced by surface adsorption of a polymer‐substituted TLR7‐agonist.